U.S. Markets close in 1 hr 48 mins

Amarantus Bioscience Holdings, Inc (AMBS)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.036+0.00 (+1.98%)
As of 1:15PM EDT. Market open.
People also watch
ELTPONCSIGXTMSTXNVIV

Amarantus Bioscience Holdings, Inc

655 Montgomery Street
Suite 900
San Francisco, CA 94111
United States
415-688-4484
http://www.amarantus.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees12

Key Executives

NameTitlePayExercisedAge
Mr. Gerald E. CommissiongChief Exec. Officer, Pres and Director230.25kN/A34
Dr. John Wesley Commissiong Ph.D.Chief Scientific Officer, Director and Member of Scientific Advisory Board179.29kN/A72
Mr. Marc E. FaerberVP of Financial Operations, Treasurer, Sec. and Corp. Controller163.34kN/A62
Mr. Rongguo Wei CPAChief Financial OfficerN/AN/A45
Dr. Elise Brownell Ph.D.Sr. VP of Operations & Project ManagementN/AN/AN/A
Amounts are as of December 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company’s diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer’s disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson’s disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson’s disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in San Francisco, California.

Corporate Governance

Amarantus Bioscience Holdings, Inc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.